Orogen Royalties Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.organon.com
- Introduction
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
The Safety and Effectiveness of MK0476 (Montelukast) in Patients With Chronic Asthma (0476-388)
Phase 1
Completed
- Conditions
- First Posted Date
- 2008-08-21
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 68
- Registration Number
- NCT00739297
Study of Nasonex in the Relief of Nasal Congestion in Patients With Seasonal Allergic Rhinitis (Study P05529)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-08-12
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 351
- Registration Number
- NCT00732381
A Long-term Study of Mometasone Furoate in Patients With Perennial Allergic Rhinitis (Study P04459)
- First Posted Date
- 2008-08-12
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 98
- Registration Number
- NCT00732368
Study of Nasonex in the Relief of Nasal Congestion in Patients With Seasonal Allergic Rhinitis (Study P05528)(COMPLETED)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-08-12
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 324
- Registration Number
- NCT00733005
Mometasone Furoate Nasal Spray for Treatment of Nasal Polyposis After Surgery (Study P03218)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-08-08
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 162
- Registration Number
- NCT00731185
Observational Study of Approaches to Lipid-Lowering Therapy in Russian Patients With Coronary Heart Disease <<Treat to Goal>> (Study P05464)
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-08-08
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 712
- Registration Number
- NCT00730132
Efficacy and Safety Study of Fosamax Plus D in Postmenopausal Women With Osteoporosis (0217A-263)
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-08-07
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 343
- Registration Number
- NCT00729651
Study of Nasonex in the Relief of Nasal Congestion in Patients With Seasonal Allergic Rhinitis (Study P05583)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-08-05
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 333
- Registration Number
- NCT00728416
Retrospective Survey Evaluating the Effectiveness and Safety of Dual Inhibition Lipid-lowering in the Treatment of Dyslipidemia (Study P05171)(COMPLETED)
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-08-01
- Last Posted Date
- 2022-02-16
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1200
- Registration Number
- NCT00726856
A Study to Investigate the Effects of Tibolone (Livial®) on Breast Tissue in Postmenopausal Women With Breast Cancer (Study 32971)(P06469)
- First Posted Date
- 2008-07-30
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 102
- Registration Number
- NCT00725374
© Copyright 2024. All Rights Reserved by MedPath